Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Case studies shed light on treatment for rare form of MCL

Mori S et al. Clin Lymphoma Myeloma Leuk. 2019 Feb;19(2):e93-7.

Publish date:: February 18, 2019

Key clinical point: Aggressive leukemic nonnodal mantle cell lymphoma (L-NN-MCL) may be highly responsive to combination therapy with rituximab and ibrutinib.

Major finding: Two patients with aggressive L-NN-MCL and P53 abnormalities who were treated with rituximab/ibrutinib and autologous stem cell transplantation remain free of disease 18 months later.

Study details: Two case reports.

Disclosures: The authors reported having no financial disclosures.

Read the Article.

Citation:

Mori S et al. Clin Lymphoma Myeloma Leuk. 2019 Feb;19(2):e93-7.